{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016168","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.565679+00:00","generated_at":"2026-05-17T05:18:38.110619+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance","bullets":["Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.","Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).","Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.","After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.","No specific exchange ratio or deal value disclosed; valuations were independent third-party."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016168","json":"https://secwatch.observer/filing/0001493152-25-016168.json","markdown":"https://secwatch.observer/filing/0001493152-25-016168.md","text":"https://secwatch.observer/filing/0001493152-25-016168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/0001493152-25-016168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:18:38.110619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d29d00471e489f010a71e54237307c808b75f0a6","claim":"MIRA PHARMACEUTICALS, INC. completed an acquisition involving SKNY Pharmaceuticals, Inc. for restricted shares of the Company’s common stock (closed 2025-09-29).","evidence_excerpt":"On September 29, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”) pursuant to the previously announced merger agreement (the “Merger Agreement”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/0001493152-25-016168-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"SKNY Pharmaceuticals, Inc."},{"label":"Consideration","value":"restricted shares of the Company’s common stock"},{"label":"Closing","value":"2025-09-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}